Skip to main content
. Author manuscript; available in PMC: 2018 Feb 20.
Published in final edited form as: Circulation. 2013 Nov 12;129(25 Suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee

Table 1.

Applying Classification of Recommendation and Level of Evidence

graphic file with name nihms936584f2.jpg

A recommendation with Level of Evidence B or C does not imply the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*

Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.

For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.